Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy for dermatofibrosarcoma protuberans.

Thomas A Abrams1, Scott M Schuetze

  • 1Division of Hematology/Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109-0848, USA.

Current Oncology Reports
|January 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

JCO precision oncology·2025
Same author

A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Dermatofibrosarcoma protuberans (DFSP), a rare skin tumor, often recurs after surgery. The drug imatinib mesylate shows promise in treating DFSP, particularly for recurrent or metastatic cases.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare, aggressive skin tumor known for local invasion and high recurrence rates post-excision.
  • DFSP pathogenesis is linked to a specific chromosomal translocation, t(17;22), creating a COL1A1-PDGFB fusion gene.
  • This genetic alteration leads to uncontrolled platelet-derived growth factor (PDGF) expression and aberrant activation of PDGF receptor beta (PDGFRβ) tyrosine kinase via an autocrine loop, driving tumorigenesis.

Purpose of the Study:

  • To evaluate the efficacy and safety of imatinib mesylate as a treatment for Dermatofibrosarcoma protuberans.
  • To investigate the role of imatinib mesylate in managing recurrent or metastatic DFSP.
  • To support ongoing clinical trials exploring imatinib mesylate's therapeutic potential in DFSP.

Related Experiment Videos

Main Methods:

  • Review of clinical evidence and ongoing phase II multicenter trials.
  • Pharmacological assessment of imatinib mesylate's inhibitory action on PDGFR tyrosine kinases.
  • Analysis of DFSP genetic and molecular mechanisms, including the t(17;22) translocation and resulting chimeric gene.

Main Results:

  • Imatinib mesylate demonstrates potent inhibition of PDGFR tyrosine kinases, including PDGFRβ.
  • Clinical data suggest imatinib mesylate is a safe and effective treatment option for DFSP.
  • The drug shows particular benefit in patients with recurrent or metastatic Dermatofibrosarcoma protuberans.

Conclusions:

  • The molecular pathway involving COL1A1-PDGFB fusion and PDGFRβ activation is critical in DFSP development.
  • Imatinib mesylate represents a targeted therapy with significant potential for DFSP treatment.
  • Further clinical investigation through ongoing trials is essential to solidify imatinib mesylate's role in DFSP management.